Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21137875 | 0.95 | PYGB (0.40) | PYGBL3MBTL1 | |
| SCHEMBL25835076 | 0.90 | PYGB (0.40) | PYGBL3MBTL1SMN1; SMN2TDP1MEN1 | |
| SCHEMBL23104867 | 0.85 | PYGB (0.41) | PYGBL3MBTL1 | |
| SCHEMBL21137906 | 0.83 | PYGB (0.44) | PYGBL3MBTL1 | |
| SCHEMBL21138646 | 0.79 | PYGB (0.38) | PYGBL3MBTL1 | |
| SCHEMBL23104868 | 0.78 | PYGB (0.37) | PYGBL3MBTL1SMN1; SMN2TDP1MEN1 | |
| SCHEMBL21137927 | 0.76 | PYGB (0.41) | PYGBL3MBTL1 | |
| SCHEMBL18391212 | 0.76 | PYGB (0.64) | PYGBL3MBTL1 | |
| SCHEMBL21137865 | 0.76 | PYGB (0.64) | PYGBL3MBTL1 | |
| SCHEMBL21138213 | 0.73 | LMNA (0.37) | PYGBL3MBTL1SMN1; SMN2TDP1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718636-B2 | Glucosamine derivatives for the prevention or treatment of joint disorders | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-08-08 | — | — | US | disclosed |
| US-20230227488-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | RISEN SUZHOU PHARMA TECH CO LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| US-11591358-B2 | Glucosamine derivatives and pharmaceutical uses thereof | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-02-28 | — | — | US | disclosed |
| US-20210079033-A1 | GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2021-03-18 | — | — | US | disclosed |
| US-20190185502-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | RISEN (SUZHOU) PHARMA TECH CO, LTD. (CN) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210079033-A1 | GLUCOSAMINE DERIVATIVES FOR THE PREVENTION OR TREATMENT OF JOINT DISORDERS | OGT, UGGT1, GLA | PYGB 760/4885L3MBTL1 3561/4885SMN1; SMN2 3123/4885 |
| US-11718636-B2 | Glucosamine derivatives for the prevention or treatment of joint disorders | OGT, UGGT1, GLA | PYGB 760/4885L3MBTL1 3561/4885SMN1; SMN2 3123/4885 |
| US-20230227488-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | OGT, UGGT1, GLA | PYGB 601/4885L3MBTL1 4558/4885SMN1; SMN2 3253/4885 |
| US-20190185502-A1 | GLUCOSAMINE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | OGT, UGGT1, GLA | PYGB 601/4885L3MBTL1 4558/4885SMN1; SMN2 3253/4885 |
| US-11591358-B2 | Glucosamine derivatives and pharmaceutical uses thereof | OGT, UGGT1, GLA | PYGB 601/4885L3MBTL1 4558/4885SMN1; SMN2 3253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.